6:34 PM
 | 
Oct 31, 2012
 |  BC Extra  |  Top Story

BioCryst falls on HCV tox concerns

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) fell $1.17 (29%) to $2.91 on Wednesday after withdrawing an IND for BCX5191 after FDA expressed concerns about the HCV candidate's preclinical toxicity profile. According to the company, the agency is concerned that exposure...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >